NCT04571138View on ClinicalTrials.gov

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 25, 2020

Primary Completion Date

August 31, 2025

Study Completion Date

February 29, 2040

Conditions
LeukemiaLymphoma
Interventions
BIOLOGICAL

SCRI-CAR22v2

Single infusion of SCRI-CAR22v2

Trial Locations (5)

20010

WITHDRAWN

Children's National Hospital, Washington D.C.

46202

RECRUITING

Riley Hospital for Children, Indianapolis

77030

RECRUITING

Texas Children's Hospital, Houston

90027

RECRUITING

Children's Hospital Los Angeles, Los Angeles

98105

RECRUITING

Seattle Children's Hospital, Seattle

All Listed Sponsors
lead

Seattle Children's Hospital

OTHER